US Pharma Tariffs Threaten Swiss Economy, Impacting Global Drugmakers
AI-Generated Summary
A Zurich economics professor warns that potential 100% US tariffs on Swiss pharmaceutical products could trigger a recession in Switzerland, significantly impacting its GDP and major drugmakers like Roche and Novartis. The proposed tariffs, aimed at encouraging US-based manufacturing, introduce considerable uncertainty regarding their scope and long-term effects on the highly export-dependent Swiss pharma sector. This development highlights the complex interplay of international trade policy, drug pricing pressures, and global pharmaceutical supply chains.
In a nutshell
This article underscores the significant geopolitical risks impacting global pharmaceutical supply chains and market access. The potential imposition of tariffs by the US could force strategic re-evaluations for major European drug manufacturers, influencing investment decisions and drug pricing models globally.
Source: Swissinfo (EN)
